

***Clostridium Difficile* Toxin Gene
Nucleic Acid Test Kit (PCR-
Fluorescent Probe Method)**

1 [Product Name]

Clostridium Difficile Toxin Gene Nucleic Acid Test Kit (PCR-Fluorescent Probe Method)

2 [Specification]

10 tests/kit (10210110A), 50 tests/kit (10210110B).

3 [Intended Use]

This kit is a qualitative in vitro diagnostic test provided for the rapid detection of *C. difficile tcdB* (toxin B gene), *cdt* (binary toxin gene), and deletion of a nucleotide at position 117 of the *tcdC* gene, from shapeless fecal samples (liquid or semi-liquid) collected from patients with suspected *Clostridium difficile* infection (CDI). This kit is planned as an aid in the diagnosis of CDI and the detection of strains potentially associated with the most severe disease states. The test uses automated, real-time polymerase chain reaction (PCR) for the detection of *tcdB*, *cdt* and the deletion of *tcdC* at position 117 associated with ribotype 027 strain. Binary toxin is produced by a limited number of *C. difficile* strains, strain 027. Detection of binary toxin in conjunction with *tcdB* is often indicative of the presence of a more severe disease state or disease recurrence. The test results of this product are for clinical reference only and should not be used as the sole criterion for clinical diagnosis. It is recommended to comprehensively analyze the patient's condition by integrating clinical manifestations, other laboratory tests, and relevant diagnostic criteria.

4 [Principle of the Procedure]

Based on the principle of fluorescent PCR technology, specific primers and probes are designed for *Clostridium Difficile*. The detection targets are as follows: *C. difficile tcdB* (toxin B gene), *cdt* (binary toxin gene), and deletion of a nucleotide at position 117 of the *tcdC* gene. This kit adopts an endogenous internal quality control to monitor the collection, transportation, extraction and amplification procedures of test samples to avoid false negative results.

This assay is only used on the iFIND® Full-Automatic Nucleic Acid Detection and Analyzer system, which automates and integrates sample purification, nucleic acid extraction, amplification, and detection. The iFIND system consists of an instrument, a PAD controller with pre-installed software, and pre-configured testing workflows. The system uses single-use, self-contained iFIND cartridges that contain the ultrasonic

buffer and amplification reagents, and function as the reaction chamber for nucleic acid extraction and PCR.

The assay is designed for unformed stool (liquid or semi-liquid) samples. All reactions occur within the sealed cartridge. Because all processing steps are fully contained and isolated within the cartridge, the risk of cross-contamination between samples is effectively minimized.

5 [Reagents]

5.1 Materials Provided

The *Clostridium Difficile* Toxin Gene Nucleic Acid Test Kit contains sufficient reagents to process 10 (10210110A) or 50 (10210110B) samples respectively.

Table 1. Components of Kit A

Cartridges	10 per kit	50 per kit
1. Bead 1, Bead 2, and Bead 3 (freeze-dried)	1 of each per cartridge	1 of each per cartridge
2. Wash Reagent	3 mL per cartridge	3 mL per cartridge
3. Sonication Reagent	3 mL per cartridge	3 mL per cartridge
Sample Preservation Solution	2 mL x 10 tubes	2 mL x 50 tubes
Disposable Transfer Pipettes	10 per kit	50 per kit
Disposable Sampling Swab	10 per kit	50 per kit
Instructions for Use	1 per kit	1 per kit

Note: The disposable transfer pipettes and swab in Kit A are externally sourced, and their shelf life is indicated on their labels.

5.2 Materials Available but Not Provided

Table 2. Components of Kit B

Components	Specifications
Positive Control	1 test per kit
Engineering bacteria containing gene fragments of <i>C. difficile tcdB</i> (toxin B gene), <i>cdt</i> (binary toxin gene), deletion of a nucleotide at position 117 of the <i>tcdC</i> gene and internal control.	
Negative Control	1 test per kit
Engineering bacteria containing gene fragment of internal control.	
Diluent	2 tubes per kit
Nuclease-free water 2 mL	

Kit B provides positive and negative controls designed to confirm proper kit function and to assess the testing environment and operator performance. The controls are recommended to be used in the following situations:

1. Initial verification: Run both positive and negative controls when using the kit for the first time.
2. Troubleshooting: If questionable or inconsistent results are obtained, run both controls to evaluate the kit, the environment, and operator handling.
3. Environmental monitoring: If contamination of the testing environment is suspected, run both controls to verify result reliability.

6 [Storage, Transport and Handling]

1. Kit A should be stored and transported at 2°C to 28°C, protected from light, and free from freezing. The kits have a shelf life of 12 months when stored under the recommended storage conditions.
2. Production date and expiration date: refer to the outer packaging.

7 [Applicable Instrument]

The Kit is compatible with the Full-Automatic Nucleic Acid Detection and Analyzer (Models: iFIND S2, iFIND S4, iFIND S8; Medical Device Registration Certificate No.: 20233221927) manufactured by RocGene (Xuzhou) Technology Co., Ltd.

8 [Specimen Collection, Handling and Storage]

8.1 Specimen Type

Unformed stool (liquid or semi-liquid)

8.2 Specimen Collection

1. Collect the unformed stool specimen in a clean container. Follow your institution's guidelines for collecting *C. difficile* testing samples.

8.3 Specimen Storage

1. Maintain recommended storage conditions to preserve specimen integrity.
2. Test specimens as soon as possible after collection. Storage conditions:
 - Room temperature (10–30 °C): up to 12 hours;
 - Refrigerated (2–8 °C): up to 3 days;
 - Frozen (–20 ± 5 °C): up to 12 months.
3. Frozen specimens must be completely thawed and mixed before use.
4. Avoid more than three freeze–thaw cycles.

9 [Assay Procedure]

9.1 Specimen Pre-processing

1. Dip a swab into the unformed stool sample for 2–4 seconds. The swab does not need to be fully saturated.
2. Immediately place the swab into the provided sample preservation solution tube. Alternatively, an eSwab system can also be used (not provided in the kit).
3. Mix the sample thoroughly by shaking the tube about 20

times or vortexing for approximately 10 seconds. If the fecal content is excessive, dilute the sample with the preservation solution until at least 0.75 mL of clear supernatant is available for pipetting before testing.

9.2 Cartridge Preparation

1. Open the cartridge lid and remove the aluminum seal.
2. Using the provided pipette, transfer 0.75 mL of the supernatant (prepared according to Section 9.1) into the sample chamber (large opening) of the cartridge.

Note: Dispense the sample slowly along the chamber wall to avoid bubbles.

3. Close the cartridge lid firmly.

Note: If repeat testing is needed, store the remaining sample at 2–8 °C for up to 3 days.

10 [Run the Test]

1. Power on the RocGene iFIND® System.
2. Log in with your username and password.
3. Wait for the system to complete the self-check. Once finished, click “OK” to enter the “Running” window and select the desired instrument unit.
4. Scan or manually enter the **Cartridge ID**; When the Cartridge ID is entered correctly, the corresponding test project will be selected automatically.
5. Scan or manually enter the **Sample ID**. The Sample ID will be inserted into the middle of the default Experiment Name.

Example: If the default name is 20250907-165208 and Sample ID 888888 is entered, the name becomes 20250907-888888-165741.

6. By default, the Experiment Name is generated from the date and time the system was powered on. Edit if needed; the name will be linked to the test results in the “Analyze” window.
7. Click “Open Door” to open the module.
8. Insert the cartridge with the amplification tube facing the inside of the module.
9. Close the door.
10. Click “Start Run” to initiate the assay.
11. When the run is complete, the indicator light will stop flashing and remain steadily illuminated.
12. After the run finishes, click “OK” in the prompt box.
13. Navigate to the **Analyze** window to review and confirm test results.

11 [Quality Control]

Table 3. Fluorescent Channels and Targets

Channel	Target
CY55	Internal Control
VIC	<i>tcdC</i>
FAM	<i>cdt</i> (binary toxin gene)
ATTO	<i>tcdB</i> (toxin B gene)
ROX	<i>TcdC-117</i> (<i>tcdC</i> deletion at nucleotide 117)

Each test includes an internal quality control (IC), which verifies that the cartridge and test process are functioning properly. If the quality control criteria are not met, the test results cannot be interpreted.

Internal Control (IC):

The internal control confirms that:

- the sample was added correctly,
- reagents are functioning as intended,
- the procedure was performed correctly, and
- no interfering substances prevented amplification.

External Controls:

External quality controls (see Section 5.2) are available but not provided. They may be used in accordance with local, state, or federal regulations, as applicable.

12 [Cutoff Values]

According to clinical sample testing, positive result thresholds were determined using ROC curve analysis.

—Positive for *cdt* (binary toxin gene): FAM channel, Ct ≤ 38.

—Positive for *tcdB* (toxin B gene): ATTO channel, Ct ≤ 38.

—Positive for 027: *tcdC-117* (*tcdC* deletion at nucleotide 117), ROX channel, Ct ≤ 38;

Identification of the ribotype 027-associated strain requires analysis of both the VIC (tcdC) and ROX (TcdC-117) channels. Please refer to the automated report for the final interpretation.

13 [Interpretation of Results]

When the instrument is operating normally and the internal control test results meet all requirements, test sample results are analyzed and interpreted. Results are automatically generated by the instrument.

Table 4. Interpretation of Results

Result	Interpretation of results & action
Positive for <i>tcdB</i> (toxin B gene)	1. The <i>toxin B gene (tcdB)</i> is present in the sample.
	2. Internal control: No requirement for internal control signals due to competition between positive sample amplification and the internal standard.
	3. Probe quality control is normal.
Positive for <i>cdt</i> (binary toxin gene)	1. The <i>binary toxin gene (cdt)</i> is present in the sample.
	2. Internal control: No requirement for internal control signals due to competition between positive sample amplification and the internal standard.
	3. Probe quality control is normal.
Positive for 027	1.The <i>tcdC</i> deletion at nucleotide 117 (<i>TcdC-117</i>) is present in the sample.
	2. Internal control: No requirement for internal control signals due to competition between positive

Negative for <i>tcdB</i> (toxin B gene)	sample amplification and the internal standard.
	3. Probe quality control is normal.
Negative for <i>cdt</i> (binary toxin gene)	1.The <i>toxin B gene (tcdB)</i> is absent in the sample or below the detection limit.
	2. Internal control: Normal amplification, indicating a normal experimental process.
	3. Probe quality control is normal.
Negative for 027	1. The <i>binary toxin gene (cdt)</i> absent in the sample or below the detection limit.
	2. Internal control: Normal amplification, indicating a normal experimental process.
	3. Probe quality control is normal.
The result needs to be repeated	1. The <i>tcdC</i> deletion at nucleotide 117 (<i>TcdC-117</i>) is absent in the sample or below the detection limit.
	2. Internal control: Normal amplification, indicating a normal experimental process.
	3. Probe quality control is normal.
	1. Uncertain presence of <i>C. difficile</i> .
	2. Internal control: amplification is abnormal, and experimental process is abnormal;
	3. Probe quality control: Invalid.

14 [Limitations]

1. The test results of this product are for clinical reference only and should not be used as the sole criterion for clinical diagnosis.
2. The primer or probe binding region is a conserved region of the pathogen, and mutations rarely occur, but genetic mutations in the epidemic process of the pathogen cannot be ruled out, resulting in false negatives.
3. Inappropriate sample collection, transportation, handling, experimental procedures, or experimental conditions, may all lead to false negative and/or false positive results.
4. Only common mutations have been validated in clinical trials, Rare or novel strains have not been clinically validated.
5. Contamination by microorganisms and amplification products may cause erroneous results. Strict attention should be paid to laboratory division and the PCR standard laboratory operation method should be followed.

15 [Analytical Performance

Characteristics]

1. **Limit of Detection (LoD)**
200 CFU/mL.
2. **Analytical specificity**
No cross-reactivity with other enteric pathogens.

16 [Warnings and Precautions]

1. For in vitro diagnostic use only. Please read the product manual carefully before operation.
2. All samples for detection should be handled as potentially infectious. Wear laboratory coats, protective disposable gloves and change the gloves often to avoid cross-contamination between samples. Handling of samples and waste must meet relevant requirements outlined in local, state and national regulations.
3. This kit does not contain active substances of human or animal origin.
4. Product performance is verified only for Unformed stool (liquid or semi-liquid) sample and the sample collection and processing method described in section 8 [Specimen Collection, Handling and Storage] . If other sample types or sample collection and processing methods are used, product performance cannot be guaranteed.
5. The kit still has a certain amount of biological load and pollutants after use, handle the reagent with appropriate precautions and good laboratory practice.
6. Note: Improper operation during the storage, transportation and use of the reagent may affect the test results. For example, improper storage and transportation, sample collection, sample processing and test process are not standardized. Please strictly follow the instructions.

Name: MedUnion S.L. (ES-AR-000019366)

Address: Carrer de Tapioles,33, 2-1,

Barcelona, 08004, Spain

Tel: +0034-644173535

Email: admin@medunion.es



17 [Key to symbols]

Symbols	Title	Symbols	Title
	CE Marking		In vitro diagnostic medical device
	Temperature Limitation		Keep away from sunlight
	Do not use if package is damaged		Do not re-use
	Consult Instruction for Use		Caution
	Manufacturer		Authorized representative in the European Community/ European Union
	Reference	/	/

18 [Basic information]

Name: RocGene (Xuzhou) Technology Limited



Address: Second Floor, Phase 1, Building 6,
No. 10 Zhujiang East Road, Third Industrial
Park, Xuzhou High-tech Industrial
Development Zone, Jiangsu Province, 221100
P.R. China